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Ionizing radiation (IR) creates lethal DNA damage that can effectively kill tumor
cells. However, the high dose required for a therapeutic outcome also damages
healthy tissue. Thus, a therapeutic strategy with predictive biomarkers to enhance
the beneficial effects of IR allowing a dose reduction without losing efficacy is
highly desirable. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in
the majority of recalcitrant solid tumors in comparison with normal tissue. Studies
have shown that NQO1 can bioactivate certain quinone molecules (e.g., ortho-
naphthoquinone and β-lapachone) to induce a futile redox cycle leading to the formation
of oxidative DNA damage, hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1),
and catastrophic depletion of NAD+ and ATP, which culminates in cellular lethality via
NAD+-Keresis. However, NQO1-bioactivatable drugs induce methemoglobinemia and
hemolytic anemia at high doses. To circumvent this, NQO1-bioactivatable agents have
been shown to synergize with PARP1 inhibitors, pyrimidine radiosensitizers, and IR.
This therapeutic strategy allows for a reduction in the dose of the combined agents to
decrease unwanted side effects by increasing tumor selectivity. In this review, we discuss
the mechanisms of radiosensitization between NQO1-bioactivatable drugs and IR with
a focus on the involvement of base excision repair (BER). This combination therapeutic
strategy presents a unique tumor-selective and minimally toxic approach for targeting
solid tumors that overexpress NQO1.
Keywords: NQO1, PARP1 hyperactivation, ionizing radiation, base excision repair, double-strand break repair,
synergy, β-lapachone, abasic sites
Abbreviations: 53BP1, tumor suppressor p53 binding protein 1; 8-oxoG, 8-Oxoguanine; AP site, apurinic/apyrimidinic site;
APE1, apurinic/apyrimidinic endonuclease 1; APE2, apurinic/apyrimidinic endonuclease 2; ATP, adenosine triphosphate;
BAPTA-AM, (1,2-bis(o-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid); BER, base excision repair; CtIP Complex,
complex involved with MRN and BRCA as a scaffold; DIC, dicoumarol; DNA pol β, DNA polymerase beta; DNA-PKcs,
DNA dependent protein kinase, catalytic subunit; DSB, double-strand break; ER, endoplasmic reticulum; gH2AX, H2A
histone family member X (phosphorylated Serine 139); Gy, gray of ionizing radiation; HAN, head and neck cancer; IR,
ionizing radiation; Ku70/Ku80, XRCC5/XRCC6; MeOX, methoxyamine; MRN, complex of Mre11, Rad50, and Nbs1 involved
in end processing; NAD+, nicotinamide adenine dinucleotide; NAMPT, nicotinamide phosphoribosyltransferase; NER,
nucleotide excision repair; NHEJ, non-homologous end-joining; NQO1, NAD(P)H:quinone oxidoreductase 1; NSCLC, non-
small cell lung cancer; OGG1, 8-Oxoguanine DNA glycosylase 1; PARylation, poly-ADP-ribosylation; PDAC, pancreatic
ductal adenocarcinoma; ROS, reactive oxygen species; RPA, replication protein A; SSB, single-strand break; ssDNA, single-
strand DNA; TNBC, triple-negative breast cancer; XRCC1, X-ray repair cross-complementing protein 1; XRCC4, X-ray repair
cross-complementing protein 4.
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INTRODUCTION
Ionizing radiation induces high levels of single-strand DNA
breaks (SSBs), double-strand DNA breaks (DSBs), and oxidized
bases via ROS production and DNA–protein cross-links that
activate almost all DNA repair pathways (1, 2). Although
effective, the toxicity of IR to healthy tissue at a therapeutic
dose presents a significant limitation in the clinic (3–5). IR
activates the BER pathway, in which DNA glycosylases (e.g.,
OGG1) create abasic sites and SSBs for base excision and
replacement (6). If these SSBs persist, are replicated through, or
are within three base pairs of each other, they are converted to
DSBs. The presence of one unrepaired DSB has been reported
to be lethal (7, 8). Thus, combining IR with an agent that
also promotes a significant increase in DNA damage through
modified bases and deleterious DSBs preferentially in tumors
may effectively reduce the necessary dose of IR in a clinical
setting to lessen toxicity to healthy tissues and improve patient
outcomes. The use of a tumor-selective drug for this purpose is
an attractive possibility.
NAD(P)H:quinone oxidoreductase 1 (NQO1, also called DT-
diaphorase) is a phase II two-electron redox enzyme that is highly
overexpressed in most solid tumor types compared with most
healthy tissues, as shown through studies by Siegel and Ross
(9, 10). Ortho-napthoquinones are a unique class of quinone
molecules that, unlike other quinones that are conjugated
to glutathione and excreted from the cell, are bioactivated
specifically by NQO1 to undergo a two-step back-reaction
with oxygen (11). In this futile cycle, NQO1 continuously
metabolizes the drugs and then reverts them to the parent
compound (12). This process causes rapid accumulation of ROS
such as superoxide radical and hydrogen peroxide (H2O2) that
permeate the cell and nuclear membrane to cause significant
numbers of oxidized bases and SSBs, which consequently lead
to the formation of lethal DSBs. Poly(ADP-ribose) polymerase-
1 (PARP1) is hyperactivated by this DNA damage, which
rapidly depletes NAD+ and ATP, causing metabolic catastrophe
and cell death via programmed necrosis (termed NAD+-
Keresis) (13).
Base excision repair is the main repair pathway involved
in activating PARP1 during the repair of SSBs and oxidized
bases (14). Depleting BER enzymes, such as XRCC1,
and modification of apurinic/apyridinic (AP) sites with
methoxyamine (MeOX) synergizes with NQO1-bioactivatable
drugs, promoting increased DSBs and rapid cell death (15).
NQO1-bioactivatable drugs have long been known to synergize
with halogenated pyrimidine radiosensitizers (16). More
recently, synergy between PARP inhibitors (17) and IR (18,
19) has been shown. The use of NQO1-bioactivatable drugs,
therefore, may be a clinically viable approach to reduce the
toxicity of IR associated with high doses and also to improve
the tumor selectivity of treatment. In this review, we discuss
the mechanisms of radiosensitization between low doses of
NQO1-bioactivatable drugs and IR—with a focus on the BER
repair pathway and PARP1 hyperactivation—and present a case
for combination treatment with NQO1-bioactivatable drugs and
IR in the clinic.
NQO1-BIOACTIVATABLE DRUGS
INDUCE A SPECIFIC FORM OF
PROGRAMMED NECROSIS
(NAD+-KERESIS)
β-Lapachone (β-lap/ARQ761 in clinical form) is an NQO1-
bioactivatable drug derived from lapachone (20), with known
antimicrobial (21) and anticancer activity as a single agent (22).
The futile redox cycling of β-lap by NQO1 (11) produces ROS-
induced DNA damage (Figure 1A), which ultimately leads to
cell death via metabolic and bioenergetic catastrophe caused
by NAD+ and ATP depletion following PARP1 hyperactivation
(23). Boothman and colleagues have shown that within 5 min
of β-lap treatment, there is a significant calcium flux from the
ER to the cytosol (24). Calcium flux from the ER is necessary to
activate calpain protease (24) and hyperactivate PARP1; however,
the mechanistic role of calcium in PARP1 hyperactivation has
yet to be firmly established (25). Within 30 min, the NAD+
molecules that are produced during the futile redox cycling
of β-lap by NQO1 are rapidly exhausted by hyperactivated
PARP1 during the repair of ROS-induced DNA damage and
SSBs (17). Depletion of NAD+ consequently depletes ATP and
induces a specific type of programmed necrosis, termed NAD+-
Keresis (26). Expression of catalase can spare cellular lethality by
neutralizing the effects of hydrogen peroxide (H2O2) produced
by β-lap (an NQO1-bioactivatable agent), confirming the role
of ROS formation in toxicity (27). Inhibition of NQO1 activity
with a small-molecule inhibitor (e.g., Dicoumarol) or genetically
knocking out NQO1 eliminates β-lap lethality, showing the
selectivity of β-lap-induced cell death to NQO1-expressing
cells (17, 23). Calcium release from the ER can be blocked
with the calcium chelator, BAPTA-AM, which prevents PARP1
hyperactivation and spares cancer cells from lethality, further
highlighting the role of PARP1 in β-lap-induced cell death (25).
When NAD+ production is inhibited genetically by depleting
NAMPT or pharmacologically with NAMPT inhibitors (e.g.,
FK866) (26) prior to β-lap treatment in NQO1-overexpressing
cancer cells, a synergistic cell death due to compromised
NAD+ production following PARP hyperactivation highlights
the critical role of catastrophic NAD+ depletion in NAD+-
Keresis (Figure 1A) (26).
TRAPPING PARP1 ON DNA SYNERGIZES
WITH NQO1-BIOACTIVATABLE DRUGS
There are 17 known PARP proteins (28) that share a common
catalytic domain but exhibit differential roles in DNA repair,
chromatin structure and modification, transcription, and cell
death. PARP proteins catalyze the transfer of one or more ADP-
ribose units to substrate proteins through a process known as
mono- or poly(ADP) ribosylation, respectively (29). Of particular
importance to the NQO1-bioactivatable drug field is PARP1,
which is required for both BER and NER to recruit and activate
SSB repair proteins (30). In BER, PARP1 forms a critical complex
with DNA ligase III, XRCC1, and DNA pol β (30).
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FIGURE 1 | PARP inhibitors switch cell death to apoptosis from programmed necrosis. (A) NOQ1 bioactivatable drug β-lap mediates a futile redox cycle with NQO1
detoxifying enzyme, creating a large pool of NAD+ and hydrogen peroxide. Hydrogen peroxide formation leads to the formation of oxidized bases and SSBs that
induces PARP1 hyperactivation. PARP1 utilizes NAD+ for activity, which depletes NAD+ and ATP, resulting in NAD+-Keresis. (B) Addition of PARP inhibitor prevents
PARP1 hyperactivation and spares ATP and NAD+. Cellular processes can then recycle NAD+ back to NAD(P)H, which power more turns of the futile cycle creating
even more oxidized bases and SSBs. PARP1 inhibition results in SSB-to-DSB conversion and death by apoptosis.
In BRCA1/2-deficient breast and ovarian cancers—which
are deficient in homologous recombination (HR) to repair
DSBs—PARP1 inhibitors are an effective therapeutic strategy
targeting repair of SSBs and BER (31). PARP trapping agents
(e.g., talazoparib, rucaparib, and olaparib) are the most effective
PARP1-targeting drugs, which trap PARP1/2 on the DNA by
binding at the active site, preventing its interaction with NAD+
and therefore preventing dissociation via the auto-PARylation
domain (32). PARP trapping prevents the recruitment of proteins
needed to complete BER, leaving unrepaired SSBs that are then
converted to lethal DSBs upon collision with the replication and
transcription machineries (31, 32).
Recently, we reported that PARP-trapping agents Rucaparib
and Talazoparib synergize with β-lap in NQO1+ lung, pancreatic,
and TNBC cell lines and in vivo models of NSCLC (17). Sublethal
β-lap doses showed significant synergy with non-toxic doses of
PARP inhibitor Rucaparib in multiple cancer types, and up to
60 different NSCLC cell lines (17). Synergy occurred regardless
of oncogenic and tumor-repressor mutations and was entirely
NQO1-dependent in all cell types (17), according to the gold
standard combinatorial index obtained using the Chou and
Talalay method (Figure 1B) (33).
Mechanistically, the addition of non-toxic doses of PARP
inhibitor (e.g., Rucaparib) to sublethal β-lap doses prevents
the loss of NAD+ and ATP (17). No PARylation of PARP1
occurred in this instance; however, DSBs significantly increased,
indicating a β-lap-mediated SSB-to-DSB conversion (17). NAD+
and ATP sparing allows for more oxygen consumption
during the futile redox cycling of NQO1-bioactivatable agents,
increasing the formation of oxidized bases and unrepaired
SSBs (17). This process overwhelms the DNA damage response
and repair (17). ATP is then used to initiate caspase-
dependent apoptosis, which is in contrast with the NAD+-
Keresis observed with β-lap monotherapy (17). PARP inhibitors,
therefore, enhance DNA damage caused by NQO1-bioactivatable
drugs and switch cell death from programmed necrosis to
apoptosis (17). This is significant as necrosis may cause
inflammation and lead to complications, whereas apoptosis
does not. Combining β-lap with PARP1 inhibitors, therefore,
reduces the toxicity of the drug in addition to enhancing
its mechanism of action, making it more attractive for
clinical application.
BER IS THE MAJOR DNA REPAIR
PATHWAY INVOLVED IN THE
NQO1-BIOACTIVATABLE DRUG
MECHANISM OF ACTION
Base excision repair resolves non-distorting DNA lesions
resulting from alkylation, oxidation, depurine/pyrimidination,
and deamination, which can be drug-induced or occur from
exposure to environmental toxins. There are two types of
BER: short patch that repairs a single damaged base and
long patch that repairs up to three damaged bases (34).
The typical mammalian BER pathway occurs as follows:
DNA glycosylases detect damaged bases and cleave the
glycosidic bond holding the damaged base to the DNA
backbone, creating an apurinic/apyridinic site (AP site). AP
sites are cleaved by AP endonucleases (APE1/APE2), allowing
DNA pol β to fill the site with the appropriate base
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(35, 36). Mechanistically, APE1 provides a significant portion
of the endonuclease activity, while APE2 provides some
endonuclease activity and a large portion of exonuclease
activity (34). Both APE1 and APE2 provide proofreading
capabilities for pol β to reduce error rates (37). DNA ligase
then seals up this stretch of DNA to finalize the DNA
repair (35).
Hydrogen peroxide induced by β-lap permeates the nucleus
and oxidizes nucleotides, particularly guanine bases (e.g., 8-oxo-
guanine or 8-oxoG) (15). Oxidized guanine (8-oxoG) formed
during treatment with β-lap recruits DNA glycosylase OGG1,
which, combined with APE1/2, produces a SSB that activates
PARP1 during BER (15). OGG1 recognizes the oxidized lesion,
cleaves at the 3′ end, and removes the lesion, in a reaction
that is catalyzed by ATP (38). It has been shown that silencing
OGG1 prevents 8-oxoG recognition and increases the overall
amount of 8-oxoG incorporated into DNA (32). This prevents
PARP1 hyperactivation, thus abrogating NAD+/ATP loss and
β-lap-mediated lethality (15). This is an important finding
and a potential route of resistance in the clinic to NQO1-
bioactivatable drugs.
Silencing the key BER protein, XRCC1, synergizes with
NQO1-bioactivatable drugs in PDAC cell lines, further indicating
that BER inactivation plays a critical role in β-lap toxicity (15).
XRCC1 is a scaffolding protein required for clearing oxidized
bases (39). PARylated-PARP1 bound to SSBs recruits XRCC1
through the BRCT 1 domain and forms a complex consisting
of XRCC1 (40), DNA pol β (41), DNA Ligase IIIα (42), and
APE1 (43). Without XRCC1, DNA base lesions and SSBs cannot
be repaired. In addition to mediating synthetic lethality, XRCC1
knockdown also depletes NAD+ levels at a higher rate than
with β-lap alone (15). XRCC1 knockdown is currently known
to be embryonic lethal and essential for mouse development
(44). NQO1-bioactivatable drug synergy with BER deficiencies in
PDAC cells indicates a potential for these drugs to be beneficial in
targeting pancreatic cancer.
Silencing OGG1 spared β-lap-mediated lethality in PDAC,
compared with XRCC1 knockdown (15). It is thought that
knockdown of OGG1 glycosylase protects PDAC cells from death
because BER is not activated if the scanning glycosylase is non-
functional. This suggests an important role for different proteins
in BER with regard to solid tumors. Alteration of expression or
mutation of different proteins in the BER pathway can either
sensitize or protect cancer cells from NQO1-bioactivatable drug-
mediated lethality.
Methoxyamine is an AP site modifier (Figure 2) used
to sensitize temozolomide-resistant glioblastoma (45) and
ovarian cancer (46). MeOX modification of AP sites prevents
their degradation, thus mitigating sodium hydroxide-mediated
hydrolysis of the DNA backbone, preventing AP site cleavage,
blocking AP endonuclease action, and preventing BER, resulting
in cell death (47). MeOX synergizes with β-lap, increasing the
number and persistence of AP sites, PARylation, and DSBs in
PDAC. This is specific to β-lap, as co-treatment with NQO1-
inhibitor dicoumarol abrogates AP site formation. β-lap and
MeOX were also shown to synergize and ultimately reduce tumor
volume in 33% of PDAC murine xenografts (15).
FIGURE 2 | Methoxyamine permanently modifies AP sites and prevents their
repair by BER. Reactive oxygen species (ROS) modify guanine bases in DNA,
which are recognized and cut by type II DNA glycosylase, OGG1, creating an
AP site. Due to OGG1 activity as a type II glycosylase, OGG1 is capable of
cleaving the AP site directly. However, under normal circumstances,
APE1/APE2 come in and cut, cleaving the AP site, which is repaired either
through short patch or long patch BER via PARP1 and XRCC1 scaffold
protein that recruit appropriate proteins (i.e., Pol β) necessary for repair.
APE1/APE2 both provide proofreading for pol-β to prevent errors in repair
(37). APE1 provides most of the endonuclease activity compared with APE2,
which provides some endonuclease activity and a large amount of
exonuclease activity (36). Methoxyamine permanently modifies the AP site
preventing PARP1 and other necessary proteins from accessing and fixing
SSBs. These SSBs are converted to DSBs and result in cell death.
DOUBLE-STRAND BREAK AND BER
PLAY A CRITICAL ROLE IN TUMOR
RESPONSE TO IR
Ionizing radiation is one of the most common and effective
methods for treating solid tumors in cancer patients. IR damages
DNA directly by causing ionization in DNA itself or indirectly by
ionizing the surrounding water resulting in aqueous free radicals
that can react with DNA. Inducing significant DNA damage by IR
over several treatments results in cancer cell death; however, there
are significant drawbacks to this approach, including limitations
on the number of IR dose a person can receive in a lifetime, costs,
the need for special diets, and serious side effects arising from
healthy tissue damage (48). IR produces 1000 SSBs, 40 DSBs,
700 altered thymine bases, 700 8-oxoG base alterations, and 150
DNA–protein cross-links per gray (Gy) (49, 50). The resistance of
cancer cells is considered to be determined by the efficacy of DSB
repair (51, 52).
Ionizing radiation-induced DSBs activate DSB repair via
NHEJ and HR (Figure 3A). NHEJ occurs in all phases of the cell
cycle (53), which is a quick and easy way to fix massive levels of
dsDNA breaks, and is utilized for V(D)J recombination for the
human immune system (52). During this process, Ku70 and Ku80
heterodimers bind the end of the double-stranded DNA breaks
and form a complex to protect and recruit DNA-PKcs (54) to
the site of the damage. XRCC4 binds to the Ku dimers through
Ku70 mediating the attachment of other proteins necessary to fix
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FIGURE 3 | Ionizing radiation induces a wide variety of DNA damage. (A) IR causes dsDNA breaks that are repaired by HR (in S/G2 phase) or NHEJ (all phases of
cell cycle). In HR, the RPA complex and BRC proteins form a scaffold complex with the sister chromatid and use it as a template to correct damage without error.
NHEJ utilizes the KU70/80/DNA-PKc complex to quickly combine and ligate double-strand breaks. (B) IR-mediated radiolysis of water leads to ROS formation,
which then creates base damage through oxidation. BER then repairs these lesions through the use of a type II DNA glycosylase (OGG1), AP endonuclease
(APE1/APE2), PARP1, DNA polymerase, and ligase. This occurs through either short patch or long patch BER.
FIGURE 4 | Proposed mechanism of IR and β-lap radiosensitization. NSCLC
tumors contain high levels of NQO1 compared to normal tissues. In the
presence of NQO1, β-lap causes ROS-induced oxidative base DNA damage,
which eventually leads to the formation of SSBs that activate PARP1. IR
induces massive SSBs through contact with DNA and oxidized bases due to
water radiolysis that require PARP1 and BER to resolve. This combination
therapy pushes cumulative amount of DNA damage high enough that
overwhelms and hyperactivates PARP1 during DNA damage response and
repair, leading to programmed necrosis. Thus, NQO1 may be used as a
predictive biomarker for selective targeting of NQO1-overexpressing cancers
with low-dose IR in combination with NQO1-bioactivatable agents as
radiosensitizers.
the damage (e.g., PNKP, APLF, and XLF) (55). Artemis trims the
complex ends (56) of the DSBs for efficient ligation of DNA ends
by DNA Ligase IV/XRCC4 complex (Figure 3A) (57) to complete
the repair of DSB.
Homologous recombination occurs specifically in the S/G2
phase of the cell cycle and uses the sister chromatid as a template
to complete repair of DSBs. HR is known as an error-free repair
and minimizes the chances of mutations of functional genes
(58). After IR creates a DSB, the MRN complex (Mre11-Rad50-
Nbs1) will bind to the ends of the breaks and recruits the CtIP
complex exonuclease to create free ends that can be modified
(59). Single-stranded DNA-binding protein (hSSB1) and RPA
bind the free single-stranded DNA after resection to prevent the
degradation, improper hybridization, or combination of DNA
ends (60). These proteins then bind to BRCA scaffold proteins
(44) that load Rad51 proteins, which are responsible for creating
a Holliday Junction to align homologous sequences with the sister
chromatid strand (Figure 3A) (61). Rad51 is then released from
the RPA complex (62); DNA is synthesized and then ligated by
DNA Ligase I (63). Up-regulation of HR or NHEJ can lead to IR
resistance and neoplastic growth.
A significant portion of DNA lesions created by IR is through
a water-mediated radiolysis reaction (64). Radiolysis of water
causes significant ROS production including extremely reactive
hydroxyl (•OH) radicals close to DNA resulting in damage that
is primarily repaired by BER (Figure 3B) (65). BER may result
in DSBs being formed by replication through lesions. If multiple
oxidized lesions are within 3 base pairs of each other and BER
enzymes cut these lesions out, this will result in the formation of
DSBs (65). In addition, mutations in bacterial BER proteins have
been known to confer resistance to IR up to 250 Gy, suggesting
that BER is necessary for sensitization of IR (65).
SUBLETHAL DOSES OF β-LAP
RADIOSENSITIZE NSCLC CELLS TO
LOW-DOSE RADIATION THERAPY
In A549 and H1650 NSCLC cell lines, a sublethal dose of β-lap
causes significant sensitization to low-dose radiation therapy,
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leading to a remarkable increase in cell death. Monotherapy with
sublethal β-lap induces minimal DSBs, and low-dose radiation
monotherapy induces characteristic increase in DSBs followed
by efficient repair (18). Combination therapy with low doses
of β-lap and radiation therapy, however, promotes rapid and
sustained 53BP1 and gamma-H2AX foci formation that is
consistent with DSB formation and compromised DSB repair
(18). In NQO1+ NSCLC luciferase murine models, β-lap and
IR combination therapy reduces tumor volume and increases
survival up to 70% in comparison with either agents alone.
Tumor tissues from mice treated with IR and β-lap demonstrated
enhanced PAR and gamma-H2AX (pS139-H2AX, surrogate
marker for DSBs) level compared with monotherapy, as well as
decreased NAD+ and ATP levels (18). Normal tissues, which
generally overexpress catalase and lack NQO1, were unaffected
by co-treatment. The BER pathway may play a crucial role in
this sensitization since β-lap treatment engages BER and PARP
hyperactivation, and IR also activates BER. Mechanistically, we
hypothesize that the combination of IR and β-lap treatment
creates cumulative clusters of oxidative DNA damage and SSBs
that result in severe PARP1 hyperactivation (inactive form of
PARP1), which compromises BER and SSB repair. SSBs that are
unrepaired are eventually converted to lethal unrepaired DSBs
due to the lack of NAD+ and ATP molecules available to activate
the efficient repair of SSBs and DSBs (Figure 4). Since most solid
tumors overexpress NQO1, combining low-dose radiation with
a sublethal concentration of β-lap may enhance tumor-selective
and targeted killing and improve patient safety by lowering
the overall doses of both agents. Using NQO1 as a predictive
biomarker, this combination treatment strategy may reduce the
impact of treatment on a patient’s lifetime exposure to IR, may cut
the costs associated with cancer treatment, and potentially reduce
the amount of time needed for therapeutic response.
OUTLOOK/FUTURE
Further work is required to fully determine the critical role of
BER in IR and β-lap combination therapy. We have previously
shown that loss of specific BER factors potentiates the lethality
of an NQO1-bioactivatable agent, β-lap, selectively in NQO1-
overexpressing solid tumors. In fact, inhibition of PARP1—a
critical factor involved in DNA damage response and repair of
modified DNA bases and SSBs—prior to treatment with NQO1-
bioactivatable drug causes a synergistic cancer cell death. Thus,
we hypothesize that PARP1-mediated BER and SSB repair are
the main DNA repair pathways that are activated by β-lap, which
promotes severe PARP1 hyperactivation and subsequent lethality
at high doses. PARP inhibitors in combination with IR and
NQO1-bioactivatable drugs may further enhance synergy seen
previously (6); however, three-drug combinations are currently
rare. Overall, combining low-dose radiation therapy with NQO1-
bioactivatable drugs may be a viable, less toxic, and more tumor-
selective strategy for treatment of various solid tumors that
overexpress a predictive biomarker, NQO1.
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